The carcinogenic potential of medroxalol hydrochloride, an antihypertensive agent with 8, adrenergic cardiac blocking properties, and pL and some a, vasodilating activity, was studied by dietary administration.
INTRODUCTION
Medroxalol hydrochloride, (5 -[2-[ [ 3 -( 1,3 -benzodioxol-5yl) -1methylpropyl]amino] -1hydroxyethyl]-2-hydroxybenzamide hydrochloride) is an antihypertensive agent with 8, adrenergic cardiac blocking properties, and p2 and some a1 vasodilating activity (3, 4) . Medroxalol has been demonstrated to be effective in lowering blood pressure in spontaneously hypertensive rats (3), and in dogs (3) and man (15) .
Beta blocking.drugs have been effective in the treatment of various cardiac disorders such as arrhythmias, angina pectoris and hypertension. The report that one such agent, pronethalol, produced lymphoreticular tumors in mice (1) caused a great deal of concern over the carcinogenic potential of #?-adrenergic antagonists, and led to U.S. requirements for carcinogenicity studies in two species (12). This requirement has been continued even though further studies with pronethalol in rats and guinea pigs failed to show an increase of tumors (6, 13) , and most of the other 8-blockers that' have been tested have not proven to be carcinogenic (5) . In a recent review of the toxicity of p-blockers, it was concluded that any carcinogenic potential of these compounds was compound specific and not due to their B blocking activity (8) .
In contrast, the Bz adrenergic receptor agonists soterenol hydrochloride (1 0), and mesuprine hydrochloride (1 1) were shown to induce mesovarial leiomyomas in rats. These were the first descriptions of this unique benign smooth muscle tumor. Later salbutamol and terbutaline were also shown to induce leiomyomas in rats, but not in mice or hamsters (7) . Several of the P2 agonists were originally thought to be devoid of this potential (7) , but it has since been concluded that any flz adrenergic agonist would be expected to produce mesovarial leiomyomas in rats if properly studied (adequate potency and bioavailability in a sensitive strain) (5, 7). Although we are aware that a few of these compounds have been tested in mice and did not appear to be tumorigenic, there is very little information on this point in the published literature. The purpose of this communication is to report the results of rat and mouse carcinogenicity studies with medroxalol hydrochloride, an a-#? blocker with p2 agonistic properties. In6.1 were conditioned to the laboratory for a minimum of 10 days. They were divided into 4 groups of 50 males and 50 females each by use of random numbers following stratification according to body weight and housed individually in suspended wire mesh cages in light, humidity and temperature controlled rooms. Deionized water was provided ad libitlati. ,Medroxalol hydrochloride was administered orally in the diet (Purina Rodent Chow) to rats for 24 months and to mice for 18 months at dosages calculated to deliver 0, 50, 250 or 500 mglkglday. On day 120 of the study, the dose for the 500 mgl kg male rats was reduced to 400 mg/kg/day because of severely reduced body weight gains. The drug diet mixture was prepared weekly, and the concentration of the drug in the diet was adjusted according to the average weekly body weight and food consumption of each male and female group. Calculation of actual drug consumption indicated that dosages were maintained at or near the proposed levels throughout the study. Each animal was observed daily while body weight, food consumption and clinical examinations were done weekly.
METHODS
After the designated period oftreatment was completed, 2 years for rats and 18 months for mice, they were fasted overnight and sacrificed by decapitation. A complete necropsy examination was done on all sacrificed animals as well as those which died or were sacrificed moribund during the study. All major organs and any tissues with visible lesions were fixed in 10% buffered formalin and examined histologically.
Statistical analyses were conducted on the incidence of leiomyomas and endometrial stromal sarcomas in the mouse. Painvise comparisons oftumor incidence for each dose group with the control were made by Fisher's exact test (16) . The tests for linear trend in proportions were made by assigning the dose levels as scores for the treatment groups, and were performed using weighted regression analysis on proportions (1 7). The mouse survival curves were also analyzed for group differences using the log rank test (9). All statistical tests were one sided.
RESULTS

Clinical Observations
Group mean body weight values for the rats (Fig.  1) revealed a dose dependent decrease in body weight gain, which was most pronounced in the males. Terminal body weights of the 50, 250 and 500 mglkg group males were 93, 77 and 68% and the females 94, 82 and 74% of control, respectively. A sialodacryoadenitis infection occurred in the rats during days 540-575 and accounted fora slight body weight decrease in every group during this period. No other significant clinical signs occurred in the 50 mg/kg group. In the 250 mg/kg group there was a mild increase in the number of rats exhibiting wet belly, and approximately 15% of these Long Evans rats exhibited a graying of their black hair. At the 500 mgkg dosage, wet belly occurred in 86% of the males and 48% of the females, ptosis occurred in 55% of the rats and more than 90% exhibited gray hair. The rat survival data ( Fig. 2) showed good viability in all groups during the first 18 months of the study (92%). During the last 6 months a number of deaths occurred in each group, with more deaths in the control and 50 mg/kg groups than in the two highest doses. Two year survival was 50% or better in every group except for the male controls (48%).
In mice there was a slight tendency for a dose related reduction in body weight gain in the males ( Fig. 3 ) but at no time during the study was the mean body weight gain ofany treated group reduced more than 9% from controls. The survival rate of treated groups (Fig. 4) was about equal to or greater than controls, with male groups having 72% to 84% survival and females having 58% to 76% survival.
No statistically significant differences (p < 0.05) were detected in the survival curves of the different treatment groups.
Necropsy Observations
None of the necropsy observations in the rats were attributed to administration of the drug. In mice the only organ in which there appeared to be a drug related effect was the uterus. This organ contained nodules and/or masses in 1 , 2,5 and 7 of the control, 50, 250 and 500 mg/kg/day mice, respectively.
Histopathologic Findings
The non-neoplastic findings did not reveal any drug related changes in either rats or mice. Neoplastic findings in rats and male mice were unaltered by treatment (Tables I and 11 ). However, in female mice there was a significant linear trend with increasing dosage in the proportion of mice with total primary neoplasms and benign neoplasms with a borderline effect on malignant neoplasms. An evaluation of individual organs and tissues revealed that these differences were, in most part, due to neoplasms of the uterus. A statistically significant increase (p < 0.05) in benign leiomyomas of the uterine muscle was seen on initial examination at 250 and 500 mg/kg/day. In addition, several endometrial stromal sarcomas were noted in the 50 and 250 mg/kg/day groups. In order to evaluate the problem in more detail and assure that no tumors would be missed, 3 additional sections of the uterus were ex- amined from each mouse. The results of the uterine tumor incidence before and after additional sections were examined are presented in Table 111 . Following the final examination, it was obvious that the 2 higher dose groups had a distinct increase in leiomyomas and that the low dose had a statistically significant (p < 0.05) increase in endometrial stromal sarcomas.
The leiomyomas (Fig. 5) were located in the myometrium or occasionally in the broad ligament and usually caused a marked distention of the wall at the site. Typically, the tumors were partially or completely demarcated from adjacent smooth muscle by a rim of condensed myometrium or a distinct change in the arrangement of the cells. The tumor cells were elongated, had baton-shaped nuclei with rounded ends and were arranged in interweaving, intersecting bundles. Abundant eosinophilic cytoplasm was present in most tumors, but was less noticeable in some of the more cellular tumors. Mitoses were rare or absent. Many of the larger tumors contained hyalinized or necrotic areas which sometimes contained foci of mineralization.
The endometrial stromal sarcomas (Fig. 6) appeared to arise in the endometrium and often bulged into the lumen ofthe uterus. Invasion of the myometrium was frequent, but metastases were not observed. The neoplastic cells were of varying sizes and shapes with pale eosinophilic cytoplasm and poorly discernible boundaries. The nuclei were round, oval, elongated or irregular in outline having fine or densely clumped chromatin with vesicular nuclei sometimes present especially in larger cells. Usually one, but sometimes several nucleoli were present and mitotic figures were common. Most cells were arranged in sheets, but fascicles of spindle shaped cells were also seen. Focal necrotic areas, sometimes containing clefts, were also observed.
DISCUSSION
Medroxalol hydrochloride did not produce any evidence of a tumorigenic effect when administered to rats for 2 years. Graying of the dark hair of the Long Evans rats was an unusual clinical sign noted in the 250 and 500 mg/kg groups. This change is probably related to the binding of medroxalol to melanin as drug distribution studies have demonstrated the retention of medroxalol in pigmented eyes, and because melanin binding has been demonstrated with labetalol, a closely related drug (14).
Mice treated with medroxalol hydrochloride for 18 months were free of significant clinical signs or pronounced effects on body weight gain, but did have an increased incidence of uterine tumors. The incidence of benign smooth muscle tumors was significantly increased at 250 and 500 mg/kg/day but not at 50 mg/kg/day. Fifty mg/kg/day was considered a no effect dose because even though no leiomyomas were seen in the control group, the incidence at 50 mg/kg was not greater than has been occasionally seen in control groups from other studies in CD-I mice. The incidence of endometrial stromal sarcoma was statistically significant only at the lowest dosage and only after additional sections were examined (Table 111 ). This effect may not be related to treatment, since there was a decreased incidence with increased dosage, and the incidence in the 2 higher dose groups was neither statistically significant nor higher than has occasionally been seen in other control groups.
Several @-adrenergic agonists have been reported to induce benign smooth muscle tumors of the mesovarial ligament in the rat. Soterenol(l0) and mesuprine (1 1) have produced leiomyomas in Sprague Dawley rats, and additional studies with soterenol indicated that Long Evans rats are also susceptible, although to a lesser degree (7) . Other primary B2 selective adrenergic agents such as salbutamol and terbutaline have also been shown to induce mesovarial leiomyoma formation (7) , and it is generally accepted that any pz adrenergic agonist would be cxpected to produce mesovarial leiomyomas in the at SAGE PUBLICATIONS on December 9, 2012 tpx.sagepub.com Downloaded from Organs without primary neoplasms, and metastatic neoplasms are not listed (other organs examined include: brain, sciatic nerve, eyes, pituitary gland, exorbital and posterior lacrimal gland, salivary gland, mandibular and mesenteric lymph nodes, thymus, esophagus, diaphragm, heart, aorta, tongue, pancreas, colon, kidney, urinary bladder, skeletal muscle, testis, epididymis, prostate and sternebra with bone marrow).
Indicates the number of animals examined for a particular organ or tissue. -Additional sections of each horn and body of uterus as well as any possible gross lesions (minimum of 3 additional sections) of each uterus examined. rat if properly studied (adequate potency and bioavailability in a sensitive strain) (7). This effect was prevented by the P-blocker piopranolol when administered in combination with salbutamol, indicating P2 adrenergic stimulation as the mechanism of induction (7). P2 adrenoceptors have been identified in mesovarial smooth muscle and have been shown to mediate smooth muscle relaxation (2); however, the mechanism by which induction of smooth muscle relaxation causes leiomyoma formation remains unclear. Studies in the mouse and hamster (7) with several of these agents have not shown mesovarial leiomyoma induction.
The failure ofmedroxalol, an agent with P2 agonist properties, to induce leiomyoma formation in the rat mesovarial ligament cannot be attributed to a lack of adsorption, as determination of uterine and plasma medroxalol levels after 3 weeks of dietary dosing at 500 mg/kg/day revealed concentrations 5 to 7 times greater in the rat than in the mouse (Table  IV) . Thus, if the rat were susceptible to uterine leiomyoma induction, as is the mouse, it should have been evident in this study. The reason why medroxalol produces different results in these species than specific P2 agonists is not clear, but may be due to some of the additional a and / 3 adrenergic activities of this compound.
